Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04559022
Other study ID # STU 2020-0310
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 30, 2020
Est. completion date December 14, 2022

Study information

Verified date January 2023
Source University of Texas Southwestern Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This single-center, clinical trial consists of a one autologous fat grafting treatment followed by 3-month and 6-month post-treatment visits in order to assess the efficacy of fat grafting when used by men and women with facial acne scars.


Description:

This investigation, pilot study will evaluate the safety and efficacy of autologous fat grafting for the treatment of acne scarring. Overall assessment of clinical outcome and safety will be based clinic visits and evaluation of pre- and post- procedural photos. In conjunction with standard and close-up photography, we will also be using 3D imaging, cross-polarized imaging, UV imaging, high-resolution ultrasonography, optical coherence tomography, transepidermal water loss measurements, and/or BTC 2000 measurements. Additionally, we will be utilizing 0.33 mm skin biopsies to assess histological and genetic changes that occur below the skin surface as a result of this treatment. The subject's assessment of satisfaction will be characterized using a non-parametric assessment scale at each follow-up period.


Recruitment information / eligibility

Status Completed
Enrollment 10
Est. completion date December 14, 2022
Est. primary completion date June 10, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria: 1. Men and women 18 to 50 years of age having general good health. 2. Individuals deemed by the Investigator to have a significant amount acne scarring on the face and that desire correction of this condition. 3. Individuals willing to withhold aesthetic therapies to the areas of the hand being treated or judged to potentially impact results by the Investigator (e.g. soft tissue fillers and/or any resurfacing procedures, botulinum toxin, injectable fillers, microdermabrasion, IPL (intense pulsed light), peels, laser treatments, and tightening treatments, etc.) for the duration of the study. Waxing and threading is allowed but no laser treatments outside of the study. 4. Individuals that are willing to provide written informed consent and are able to read, speak, write, and understand English. 5. Individuals willing to sign a photography release. 6. Willingness to cooperate and participate by following study requirements for the duration of the study and to report any changes in health status or medications, adverse event symptoms, or reactions immediately. Exclusion Criteria: 1. Individuals diagnosed with known allergies to general skin care products. 2. Individuals who have presence of an active systemic or local skin disease that may affect wound healing. 3. Individuals with sensitivity to topical lidocaine. 4. Individuals who have physical or psychological conditions unacceptable to the Investigator. 5. Individuals who have a recent history of significant trauma to the areas to be treated (< 6 months). 6. Individuals who have severe or cystic active and clinically significant acne on the area(s) to be treated. Clinically significant acne is defined as a subject whom has > 5 active inflammatory acne lesions (including acne conglobate, nodules, or cysts) in either the right or left treatment area. 7. Individuals who have a recent or current history of inflammatory skin disease, infection, unhealed wound or clinically significant acne in the proposed treatment areas. 8. Individuals who have a history of systemic granulomatous diseases, active or inactive, (e.g. Sarcoid, Wegeners, TB, etc.) or connective tissue diseases (e.g. lupus, dermatomyositis, etc.). 9. Individuals who currently have or have a history of hypertrophic scars, or keloid scars. 10. Individuals who currently have cancerous or pre-cancerous lesions in the areas to be treated and/or with a history of skin cancer. 11. Individuals who have the inability to understand instructions or to give informed consent. 12. Individuals who have had microdermabrasion or glycolic acid treatment to the treatment area(s) within one month prior to study participation or who will have this treatment during the study. 13. Individuals who have a history of chronic drug or alcohol abuse. 14. Individuals undergoing concurrent therapy that, in the Investigator's opinion, would interfere with the evaluation of the safety or efficacy of the study device. 15. Individuals who, in the Investigator's opinion, have a history of poor cooperation, noncompliance with medical treatment, or unreliability. 16. Individuals who have a history of the following cosmetic treatments in the area(s) to be treated: - Skin tightening procedure within the past year; - Injectable filler of any type within the past: - 12 months for Hyaluronic acid fillers (e.g. Restylane) - 12 months for Ca Hydroxyapatite fillers (e.g. Radiesse) - 24 months for Poly-L-Lactic acid fillers (e.g. Sculptra) - Ever for permanent fillers (e.g. Silicone, ArteFill) - Neurotoxins within the past three months; - Ablative resurfacing laser treatment; - Non-ablative, rejuvenative laser or light treatment within the past six months; - Surgical dermabrasion; - Had a chemical peel or dermabrasion, of the dorsum of the hand within four weeks 17. Individuals with a history of using the following prescription medications: - Accutane or other systemic retinoids within the past six months; - Topical Retinoids within the past two weeks; - Prescription strength skin lightening devices (e.g. hydroquinone, tretinoin, AHA, BHA and polyhydroxy acids, 4-hydroxyanisole alone or in combination with tretinoin, etc.) within four months; - Any anti-wrinkle, skin lightening devices, or any other device or topical or systemic medication known to affect skin aging or dyshcromia (devices containing alpha/beta/poly-hydroxy acids, vitamin C, soy, Q-10, hydroquinone; systemic or licorice extract (topically), Tego® Cosmo C250, gigawhite, lemon juice extract (topically), emblica extract, etc.) within two weeks; - Antiplatelet agents/Anticoagulants (Coumadin, Heparin, Plavix, chronic NSAID use); and/or - Psychiatric drugs that in the Investigator's opinion would impair the subject from understanding the protocol requirements or understanding and signing the informed consent. 18. Individuals who are nursing, pregnant, or planning to become pregnant during the study according to subject self-report. 19. Individuals having a health condition and/or pre-existing or dormant dermatologic disease on the body (e.g., psoriasis, rosacea, eczema, seborrheic dermatitis, vitiligo, hyper or hypo-skin pigmentation conditions such as post inflammatory hyperpigmentation) that the Investigator or designee deems inappropriate for participation or could interfere with the outcome of the study. 20. Individuals with a history of immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or currently using immunosuppressive medications (e.g., azathioprine, belimumab, cyclophosphamide, Enbrel, Imuran, Humira, mycophenolate mofetil, methotrexate, prednisone, Remicade, Stelara.) and/or radiation as determined by study documentation. 21. Individuals with an uncontrolled disease such as asthma, diabetes, hyperthyroidism, medically significant hypertension or hypothyroidism. Individuals having multiple health conditions may be excluded from participation even if the conditions are controlled by diet, medication, etc. 22. Individuals with any planned surgeries, overnight hospitalization, and/or invasive medical procedures during the course of the study. 23. Individuals who have observable suntan, nevi, excessive hair, etc. or other dermal conditions on the back of the hand that might influence the test results in the opinion of the Investigator or designee. 24. Individuals who have any condition, which in the opinion of the Investigator makes the patient unable to complete the study per protocol (e.g. patients not likely to avoid other cosmetic treatments to the treatment area; patients not likely to stay in the study for its duration because of other commitments, concomitant conditions, or past history; patients anticipated to be unreliable, or patients who have a concomitant condition that may develop symptoms that might confuse or confound study treatments or assessments).

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Fat Grafting
This single-center, clinical trial will assess the efficacy and tolerability of the autologous fat grafting when used on men and women with acne scars on the face.

Locations

Country Name City State
United States University of Texas Southwestern Medical Center Dallas Texas

Sponsors (1)

Lead Sponsor Collaborator
University of Texas Southwestern Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Facial Photograph Assessments Photographs will be used to evaluate efficacy of treatment. The photographs from final visit will be compared to their baseline photographs and visually evaluated by the study team.
Acne scars on patients will be assessed using the Clinician's Global Assessment Improvement Scale (CGAIS)
Baseline and 6 Months
Primary Change in Volume (MiraVex) MiraVex will be used to assess changes in volume of the subjects facial acne scars. Baseline and 6 Months
Primary VISIA Complexion Analysis: Change in Spots The VISIA will be used to objectively measure spots Baseline, 3 Months, and 6 Months
Primary VISIA Complexion Analysis: Change in wrinkles The VISIA will be used to objectively measure wrinkles. Baseline, 3 Months, and 6 Months
Primary VISIA Complexion Analysis: Change in Texture The VISIA will be used to objectively measure texture. Baseline, 3 Months, and 6 Months
Primary VISIA Complexion Analysis: Change in Pores The VISIA will be used to objectively measure pores. Baseline, 3 Months, and 6 Months
Primary VISIA Complexion Analysis: Change in UV Spots The VISIA will be used to objectively measure UV spots Baseline, 3 Months, and 6 Months
Primary VISIA Complexion Analysis: Change in Brown Spots The VISIA will be used to objectively measure brown spots. Baseline, 3 Months, and 6 Months
Primary VISIA Complexion Analysis: Change in Red Areas The VISIA will be used to objectively measure red areas Baseline, 3 Months, and 6 Months
Primary VISIA Complexion Analysis: Change in Porphyrins The VISIA will be used to objectively measure porphyrins. Baseline, 3 Months, and 6 Months
Primary Transepidermal Water Loss (TEWL) Measurements: Change in Epidermal Layer Measurements will be used to evaluate barrier function of the skin epidermal layer to determine progress of epidermal healing after treatment. Baseline, 3 Months and 6 Motnhs
Primary High Resolution Ultrasound: Change Dermal Thickness Dermal thickness will be measured via high resolution ultrasound prior to treatment (baseline), 3 months and 6 months post treatment. The change from baseline was calculated at each time frame. Baseline, 3 Months and 6 Months
Primary High Resolution Ultrasound: Change in Epidermal Thickness Epidermal thickness will be measured via high resolution ultrasound prior to treatment (baseline), 3 months and 6 months post treatment. The change from baseline was calculated at each time frame. Baseline, 3 Months and 6 Months
Primary BTC2000: Change in Skin Elasticity Skin Elasticity will be measured via BTC2000 prior to treatment (baseline), 3 months and 6 months post treatment. The change from baseline was calculated at each time frame. Baseline, 3 Months and 6 Months
Primary BTC 2000: Change in Skin Laxity Skin Laxity will be measured via BTC2000 prior to treatment (baseline), 3 months and 6 months post treatment. The change from baseline was calculated at each time frame. Baseline, 3 Months and 6 Months
Primary Histological Analysis Relative changes in protein abundance in biopsies taken at post treatment compare to control or entreated group will be quantified using an image processing software based on fluorescence signal intensity. The change from baseline was calculated at each time frame. Baseline, 3 Months and 6 Months
Primary Gene Expression Biopsies of the treated are will be taken prior to treatment and post treatment for gene expression analysis. This analysis will identify gene expression related to collagen formation and increased cell turnover. Baseline, 3 Months and 6 Months
Primary Change in Blood Flow Blood Flow will be measured via optical coherence tomography prior to treatment (baseline), 3 months and 6 months post treatment. Baseline, 3 Months and 6 Months
Primary High Resolution Ultrasound: Change in Epidermal Density Epidermal thickness will be masured via high resolution ultrasound prior to treatment (baseline), 3 months and 6 months post treatment. The change from baseline was calculated at each time frame. Baseline, 3 Months, and 6 Months
See also
  Status Clinical Trial Phase
Completed NCT05097157 - Study To Assess A Radiofrequency Microneedling Device For Dermatologic Conditions N/A
Completed NCT05131373 - Safety, Tolerability, and Immunogenicity of ORI-A-ce001 for the Treatment of Acne Vulgaris Phase 1
Completed NCT04806594 - Clinical Investigation on the Safety and Clinical Performance of Papix Acne Scar. N/A
Recruiting NCT03465150 - Creation of a Monocentric Cohort of Patients Treated for Acne at the Nantes University Hospital
Completed NCT02250859 - A Pharmacokinetic Study of Minocycline in Male and Female Volunteers Phase 1
Completed NCT01206348 - Combination Treatment for Moderate to Severe Acne Phase 4
Terminated NCT01193764 - Study Assessing the Effect of Chocolate Consumption in Subjects With A History of Acne Vulgaris N/A
Completed NCT00725439 - An Open Label Trial to Assess the Safety and Efficacy of Oral R115866 in the Treatment Facial Acne Phase 2
Completed NCT05640388 - Assessment of a Cosmetic Product Effect on the Host/Microorganism Relationship in Acneic Subjects
Completed NCT04873089 - Efficacy Study of Cosmetic Product RV3278AET0943 Versus Non-treated Group in Adults With Oily and Acne Prone Skin
Recruiting NCT05941065 - Study of Skin Balancing Gel Cream Safety and Influence of Skin Microbiome on Acne Prone Skin N/A
Recruiting NCT06120452 - A Clinical Trial to Evaluate the Effectiveness of an Acne Serum in Improving Facial Acne and Post-Acne Pigmentation N/A
Completed NCT04300010 - Blue Light Therapy of C. Acnes Phase 4
Recruiting NCT06202274 - Clinical Study to Evaluate the Safety and Efficacy of Candela Technology N/A
Terminated NCT02431494 - Safety and Preliminary Efficacy of Combination Therapy for the Treatment of Acne Vulgaris N/A
Completed NCT05469880 - Efficacy and Tolerance of Formula 609613 37 in Acneic Patients N/A
Completed NCT02944461 - Efficacy and Safety of Aczone 7.5% Gel in the Treatment of Truncal Acne Vulgaris Phase 4
Completed NCT01951417 - Adapalene BPO Gel Pump, Moisturizer SPF 30 and Foam Wash in Patients With Mild to Moderate Acne Vulgaris Phase 4
Completed NCT01701024 - Clinical Study to Test the Efficacy and Safety of ACYC to Treat Moderate to Severe Acne Phase 3
Completed NCT01245946 - Photodynamic Therapy Compared to Adapalene 0.1% Gel Plus Doxycycline in the Treatment of Acne Vulgaris Phase 2